



New Drug

Ceftobiprole Medocaril (Zevtera)

Why it matters:



Antibiotic options are limited for treating methicillin-resistant *Staphylococcus aureus* (MRSA) infections. Ceftobiprole medocaril is a prodrug of active ceftobiprole and is the second available IV cephalosporin antibiotic that can target MRSA, similar to ceftaroline.

What else to know:



Ceftobiprole may cause nausea, vomiting, anemia, or liver injury. Avoid use in ventilator-associated pneumonia since studies suggest ceftobiprole may have higher mortality.

| | |
|-------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Manufacturer | Basilea Pharmaceutica International Ltd |
| Approved use | <ul style="list-style-type: none">• <i>Staphylococcus aureus</i> bacteremia (including MRSA) in adults.• Acute bacterial skin and skin structure infections in adults.• Community-acquired pneumonia (CAP) in ages 3 months and up. |
| Approval date | April 2024 |
| Anticipated availability | Available now |
| Dosage and administration (adults) | <ul style="list-style-type: none">• Skin infections and CAP: 667 mg IV every 8 hours.• Blood stream infections: 667 mg IV every 6 hours for 8 days, then 667 mg IV every 8 hours thereafter.• Infuse each dose over 2 hours.• Reduce dose for CrCl <50 mL/min and increase frequency to every 6 hours if CrCl >150 mL/min, regardless of indication. |
| Storage requirements | <ul style="list-style-type: none">• Refrigerate unopened vials and prepared doses at 2 to 8°C and protect from light.• Beyond-use dates for prepared doses range from 24 to 94 hours depending on the diluent and ceftobiprole concentration.• Light protection is not required during administration. |
| Prescribing information | https://innovivaspecialtytherapeutics.com/products/ |



New Drug

Ceftobiprole Medocaril (Zevtera)

References:

- Holland TL, Cosgrove SE, Doernberg SB, et al. Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia. N Engl J Med. 2023 Oct 12;389(15):1390-1401.
- Overcash JS, Kim C, Keech R, et al Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET). Clin Infect Dis. 2021 Oct 5;73(7):e1507-e1517.
- Nicholson SC, Welte T, File TM Jr, et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents. 2012 Mar;39(3):240-6.
- Product information for ceftobiprole medocaril (Zevtera). Basilea Pharmaceutica International Ltd. 4123 Allschwil, Switzerland. April 2024.

Users of this resource are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and internet links in this article were current as of the date of publication.

Copyright © 2025 by Therapeutic Research Center. All Rights Reserved. trchealthcare.com